Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Harvey RD. Clin Pharmacol. 2014 May 8;6:87-96. eCollection 2014. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Bringhen S et al. Blood. 2014 May 22. pii: blood-2014-03-563759. [Epub ahead of…
DetailsUpdates to the guidelines for the diagnosis and management of multiple myeloma. Pratt G et al. Br J Haematol. 2014 May 7. doi: 10.1111/bjh.12926. [Epub ahead of print]. Multiple myeloma: advances reported in 2013 are useful in the clinic. Anderson K. J Natl Compr Canc Netw. 2014 May;12(5 Suppl):808-11. Role of new drugs incorporated into…
DetailsRisk stratification of patients with multiple myeloma prior to autologous stem cell transplantation: what is the role of serum ferritin levels? Shimoni A. Leuk Lymphoma. 2014 May 14:1-7. [Epub ahead of print]. Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Rocci A et al. Leukemia. 2014 May 12. doi: 10.1038/leu.2014.155. [Epub ahead…
DetailsClinical benefits of femoroplasty: a nonsurgical alternative for the management of femoral metastases. Plancarte R et al. Pain Physician. 2014 May-Jun;17(3):227-34. Comparative Effectiveness on Survival of Zoledronic Acid versus Pamidronate in Multiple Myeloma. Sanfilippo K et al. Leuk Lymphoma. 2014 May 21:1-22. [Epub ahead of print]. Aprepitant for the control of delayed nausea and vomiting…
DetailsEndocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma. Greenfield DM et al. Bone Marrow Transplant. 2014 May 19. doi: 10.1038/bmt.2014.103. [Epub ahead of print]. Secondary osteoporosis and metabolic bone disease in patients 50 years and older with osteoporosis or with a recent clinical fracture: a clinical perspective. Bours…
DetailsBortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. Leiba M et al. Br J Haematol. 2014 May 26. doi: 10.1111/bjh.12946. [Epub ahead of print]. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for newly diagnosed myeloma multiple patients. Blanes M…
DetailsThe British Committee for Standards in Haematology (BCSH) and the United Kingdom Myeloma Forum (UKMF) Guideline for the Diagnosis and Management of Myeloma has recently been updated. Originally published in 2011, the latest changes to the guideline include the following recommendations: cytogenetic analysis should be performed in all patients at diagnosis; a second autologous stem…
DetailsClinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Vrana JA et al. Haematologica. 2014 Apr 18. [Epub ahead of print]. A case of CD138-/CD19+/CD4+ IgD plasma cell leukemia. Sorigue M et al. Cytometry B Clin Cytom. 2014 Apr 9. doi: 10.1002/cyto.b.21173. [Epub ahead of print]. A rare cause…
DetailsUnited Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma. Rabin N et al. Int J Lab Hematol. 2014 Mar 27. doi: 10.1111/ijlh.12205. [Epub ahead of print]. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow…
DetailsAdvanced lytic lesion is a poor mobilization factor in peripheral blood stem cell collection in patients with multiple myeloma. Jung SH et al. J Clin Apher. 2014 Apr 25. doi: 10.1002/jca.21326. [Epub ahead of print]. Clinical features, outcome and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the…
Details